The disclosure relates to a method for managing the risk of dronedarone/calcium channel blockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patients also expecting to receive a calcium channel blockers treatment, by performing the following steps: a—initiate calcium channel blockers treatment at a low dose; b—performing a electrocardiogram (ECG) verification of good tolerability; c—increase of calcium channel blockers dose only if results in step b) are satisfying.